Clinical and biological adverse prognostic factors in NMZL
| Factor . | PFS . | OS . | ||
|---|---|---|---|---|
| N= . | Reference . | N= . | Reference . | |
| Age >60 y | 36 | 18 | 47; 65; 4188* | 14; 19; 10 |
| Elevated LDH | 36 | 18 | 47 | 14 |
| Hb <12 g/dL | 36; 47 | 18; 14 | 36 | 18 |
| BM+ | 36 | 18 | 36; 47 | 18; 14 |
| ECOG ≥2 | 36 | 18 | 36 | 18 |
| Stage III/IV | 36 | 18 | 36; 4188* | 18; 10 |
| B symptoms | 47 | 14 | 36; 4188* | 18; 10 |
| No anthracycline | 36 | 18 | ||
| Survivin | 27 | 16 | ||
| Caspase 3 | 27 | 16 | ||
| FLIPI 3-5 | 32 | 20 | ||
| Male | 4188* | 10 | ||
| HCV+ | 47 | 14 | ||
| Cyclin E | 27 | 16 | ||
| Ki67 | 12 | 48 | ||
| IRF4 | 12 | 48 | ||
| FLIPI 3-5 | 32 | 20 | ||
| Factor . | PFS . | OS . | ||
|---|---|---|---|---|
| N= . | Reference . | N= . | Reference . | |
| Age >60 y | 36 | 18 | 47; 65; 4188* | 14; 19; 10 |
| Elevated LDH | 36 | 18 | 47 | 14 |
| Hb <12 g/dL | 36; 47 | 18; 14 | 36 | 18 |
| BM+ | 36 | 18 | 36; 47 | 18; 14 |
| ECOG ≥2 | 36 | 18 | 36 | 18 |
| Stage III/IV | 36 | 18 | 36; 4188* | 18; 10 |
| B symptoms | 47 | 14 | 36; 4188* | 18; 10 |
| No anthracycline | 36 | 18 | ||
| Survivin | 27 | 16 | ||
| Caspase 3 | 27 | 16 | ||
| FLIPI 3-5 | 32 | 20 | ||
| Male | 4188* | 10 | ||
| HCV+ | 47 | 14 | ||
| Cyclin E | 27 | 16 | ||
| Ki67 | 12 | 48 | ||
| IRF4 | 12 | 48 | ||
| FLIPI 3-5 | 32 | 20 | ||
BM, bone marrow; ECOG, Eastern Cooperative Oncology Group; Hb, hemoglobin; LDH, lactate dehydrogenase.
Lymphoma-specific survival.